<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541058</url>
  </required_header>
  <id_info>
    <org_study_id>AD202</org_study_id>
    <nct_id>NCT02541058</nct_id>
  </id_info>
  <brief_title>Non-Invasive Chromosomal Evaluation of 22q11.2</brief_title>
  <acronym>22Q</acronym>
  <official_title>Non-Invasive Chromosomal Evaluation of 22q11.2 Using Cell-free Fetal DNA From Maternal Plasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cindy Cisneros</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roche Sequencing Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to develop and evaluate a cell-free fetal DNA test (Harmony)
      for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of Ariosa 22q.11.2 deletion/duplication assay in prenatal patients</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">420</enrollment>
  <condition>22q.11.2 Deletion/Duplication</condition>
  <arm_group>
    <arm_group_label>Confirmed 22q.11.2 deletion/duplication</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected 22q.11.2 deletion/duplication</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women carrying a fetus at risk or a confirmed fetus with 22q11.2
        deletion/duplication. A person confirmed to have 22q11.2 deletion/duplication or a
        biologically related parent of a child that has chromosomal deletion/duplication in the
        region of 22q11.2.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is â‰¥18 years of age and able to provide consent or, if under the age of 18,
             the patient has parental consent and child assent provided as required by the
             governing ethics committee.

          2. If pregnant, patients must have a singleton pregnancy and be at least 10 weeks
             gestation at the time of the study blood draw.

          3. Patients must meet at least one of the following conditions at the time of enrollment:

               1. are pregnant with abnormal fetal cardiac findings on ultrasound and is undergoing
                  evaluation with prenatal genetic testing or planned post-natal genetic testing in
                  the immediate newborn period;

               2. are pregnant with fetal ultrasound findings consistent with a 22q11.2
                  deletion/duplication phenotype and is undergoing evaluation with prenatal genetic
                  testing or planned post-natal genetic testing in the immediate newborn period;

               3. are pregnant with a fetus known to have a 22q11.2 deletion/duplication confirmed
                  by genetic testing with documentation is available;

               4. are biologically related parent of an enrolled child has chromosomal
                  deletion/duplication in the region of 22q11.2;

          4. If the site is selected to enroll control patients, they must be pregnant women
             undergoing prenatal genetic evaluation for 22q11.2 deletion/duplication.

        Exclusion Criteria

        Patients meeting any of the following criteria will be excluded from the study:

        1. Patient has history of malignancy treated with chemotherapy and/or major surgery, or
        bone marrow transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Roche Sequencing Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Fetal Medicine Foundation Belgium</name>
      <address>
        <city>Brussles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Roche Sequencing Solutions</investigator_affiliation>
    <investigator_full_name>Cindy Cisneros</investigator_full_name>
    <investigator_title>CRA</investigator_title>
  </responsible_party>
  <keyword>Velocardiofacial Syndrome</keyword>
  <keyword>Shprintzen Syndrome</keyword>
  <keyword>Conotruncal Defects</keyword>
  <keyword>Chromosomal Abnormalities</keyword>
  <keyword>22q, 22q.11.2</keyword>
  <keyword>deletion</keyword>
  <keyword>duplication</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

